Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen launches new multiple myeloma drug Kyprolis in the UK

Amgen launches new multiple myeloma drug Kyprolis in the UK

15th February 2016

Amgen has announced the UK launch of Kyprolis, a new treatment for relapsed multiple myeloma patients.

The drug has been approved in Europe for use in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

It is the first licensed irreversible proteasome inhibitor for use in combination treatment of patients with relapsed multiple myeloma, with clinical trial results showing its progression-free survival benefits compared to lenalidomide and dexamethasone alone.

Amgen expects to make a submission to the National Institute for Health and Care Excellence later in 2016, in the hope of ensuring the drug can be provided through the NHS.

Tony Patrikios, executive medical director at Amgen UK, said: "We deeply appreciate the commitment of patients in over 20 UK clinical centres who have participated in clinical trials that has allowed us to bring carfilzomib to patients in the UK."

Multiple myeloma is an aggressive form of cancer, with less than half of patients surviving for five years. It caused more than 2,700 deaths in the UK in 2012.ADNFCR-8000103-ID-801812557-ADNFCR

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.